Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).

Authors

Wenfeng Fang

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Wenfeng Fang , Jun Jia , Guanming Jiang , Xiaofang Dong , Zongxiao ShangGuan , Zhengxiang Han , Hong Shen , Li Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

First Author: Eisaku Miyauchi

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Intercalating and maintenance use of gefitinib plus chemotherapy versus chemotherapy alone in selected advanced NSCLC(ISCAN,CTONG-1102): A multicentre, open-label, randomised, phase 3 study.

First Author: Shun Lu

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902.

First Author: Satoshi Oizumi

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).

First Author: Yuki Sato